

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	786	(514/301,546/114).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2007/12/12 11:12
L2	23	l1 and selectin	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2007/12/12 11:12

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JUL 02	LIMEDLINE coverage updated
NEWS	3	JUL 02	SCISEARCH enhanced with complete author names
NEWS	4	JUL 02	CHEMCATS accession numbers revised
NEWS	5	JUL 02	CA/CAPLUS enhanced with utility model patents from China
NEWS	6	JUL 16	CAPLUS enhanced with French and German abstracts
NEWS	7	JUL 18	CA/CAPLUS patent coverage enhanced
NEWS	8	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS	9	JUL 30	USGENE now available on STN
NEWS	10	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS	11	AUG 06	FSTA enhanced with new thesaurus edition
NEWS	12	AUG 13	CA/CAPLUS enhanced with additional kind codes for granted patents
NEWS	13	AUG 20	CA/CAPLUS enhanced with CAS indexing in pre-1907 records
NEWS	14	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS	15	AUG 27	USPATOLD now available on STN
NEWS	16	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS	17	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS	18	SEP 13	FORIS renamed to SOFIS
NEWS	19	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS	20	SEP 17	CA/CAPLUS enhanced with printed CA page images from 1967-1998
NEWS	21	SEP 17	CAPLUS coverage extended to include traditional medicine patents
NEWS	22	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	23	OCT 02	CA/CAPLUS enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS	24	OCT 19	BEILSTEIN updated with new compounds
NEWS	25	NOV 15	Derwent Indian patent publication number format enhanced
NEWS	26	NOV 19	WPIX enhanced with XML display format
NEWS	27	NOV 30	ICSD reloaded with enhancements
NEWS	28	DEC 04	LINPADOCDB now available on STN
NEWS EXPRESS	19	SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.	
NEWS HOURS		STN Operating Hours Plus Help Desk Availability	
NEWS LOGIN		Welcome Banner and News Items	
NEWS IPC8		For general information regarding STN implementation of IPC 8	

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 11:14:33 ON 12 DEC 2007

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 11:14:43 ON 12 DEC 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 11 DEC 2007 HIGHEST RN 957570-32-0

DICTIONARY FILE UPDATES: 11 DEC 2007 HIGHEST RN 957570-32-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10543065.str



chain nodes :

10 11 12 19 21 22 23 25 26 27 28

ring nodes :

1 2 3 4 5 6 7 8 9 13 14 15 16 17 18

ring/chain nodes :

20
chain bonds :
8-10 10-11 10-23 11-12 11-13 14-26 15-25 16-19 17-28 18-27 19-20 19-21
19-22
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 13-14 13-18 14-15 15-16 16-17
17-18
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 5-6 8-10 10-11 11-12 16-19 19-20 19-21 19-22
exact bonds :
5-7 6-9 7-8 8-9 10-23 11-13 14-26 15-25 17-28 18-27
normalized bonds :
13-14 13-18 14-15 15-16 16-17 17-18
isolated ring systems :
containing 1 : 13 :


Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS
20:CLASS 21:CLASS 22:CLASS 23:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 11:15:00 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 206 TO ITERATE

100.0% PROCESSED 206 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

50 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**
PROJECTED ITERATIONS: 3259 TO 4981
PROJECTED ANSWERS: 3027 TO 4693

L2 50 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 11:15:04 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 3831 TO ITERATE

100.0% PROCESSED 3831 ITERATIONS
SEARCH TIME: 00.00.01

3524 ANSWERS

L3 3524 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

172.10

172.31

FILE 'CAPLUS' ENTERED AT 11:15:11 ON 12 DEC 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 12 Dec 2007 VOL 147 ISS 25

FILE LAST UPDATED: 11 Dec 2007 (20071211/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:


<http://www.cas.org/infopolicy.html>

=> s l3 full

L4 3 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:1331198 CAPLUS
DOCUMENT NUMBER: 146:184625
TITLE: 3D pharmacophore based virtual screening of T-type calcium channel blockers
AUTHOR(S): Doddareddy, Munikumar Reddy; Choo, Hyunah; Cho, Yong Seon; Rhim, Byewhon; Koh, Hun Yeong; Lee, Jung-Ha; Jeong, Seong-Woo; Pae, Ae Nim
CORPORATE SOURCE: Life Science Division, Korea Institute of Science and Technology, Seoul, 130-650, S. Korea
SOURCE: Bioorganic & Medicinal Chemistry (2007), 15(2), 1091-1105
CODEN: BMECEP; ISSN: 0968-0896
PUBLISHER: Elsevier Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
GI




AB Virtual screening of the com. databases was done by using a three dimensional pharmacophore previously developed for T-type calcium channel blockers using CATALYST program. Biol. evaluation of 25 selected virtual hits resulted in the discovery of a highly potent compound (1) with IC50 value of 0.10 µM, eight times as potent as the known selective T-type calcium channel blocker, mibefradil. Search for similar compds. yielded several hits with micro-molar IC50 values and high T-type calcium channel selectivity. Based on the structure of the virtual hits, small mol. libraries with novel scaffolds were designed, synthesis and biol. evaluation of which are currently in progress. This result shows a successful example of ligand based drug discovery of potent T-type calcium channel blockers.
IT 449767-52-6
RI: PAC (Pharmacological activity); FRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(3D pharmacophore based virtual screening of T-type calcium channel blockers)
RN 449767-52-6 CAPLUS
CN Thieno[2,3-c]pyridine-3-carboxylic acid, 6-ethyl-4,5,6,7-tetrahydro-2-[[4-([methylphenylamino)sulfonyl]benzoyl]amino]-, ethyl ester (CA INDEX NAME)

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:681500 CAPLUS
DOCUMENT NUMBER: 141:195321
TITLE: Pharmaceutical compositions comprising thieno[2,3-c]pyridines
INVENTOR(S): Gregor, Paul; Harris, Nicholas; Koppel, Juraj; Zhuk, Regina
PATENT ASSIGNEE(S): Rimonyi Pharmaceuticals Ltd., Israel
SOURCE: PCT Int. Appl., 87 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004069149	A2	20040819	WO 2004-11121	20040205
WO 2004069149	A3	20041125		
V: AK, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, RW, BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004210241	A1	20040819	AU 2004-210241	20040205
CA 2515102	A1	20040819	CA 2004-2515102	20040205
EP 1589970	A2	20051102	EP 2004-708427	20040205
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1771037	A	20060510	CN 2004-80009369	20040205
JP 200616610	T	20060706	JP 2006-502633	20040205
IN 2005DN03405	A	20070601	IN 2005-DN3405	20050801
MX 2005PA08397	A	20060217	MX 2005-PA8397	20050805
US 2006135529	A1	20060622	US 2005-543065	20051019
PRIORITY APPLN. INFO.: IL 2003-154306 A 20030205 WO 2004-11121 W 20040205				


OTHER SOURCE(S): MARPAT 141:195321
AB The present invention provides thieno[2,3-c]pyridines, and pharmaceutical compns. comprising thieno[2,3-c]pyridines. The compds. capable of inhibiting glycosaminoglycan (GAG) interactions with effector cell adhesion molts. (ECAM) are useful for treating diseases and disorders mediated by GAG-ECAMs interactions, particularly inflammatory and autoimmune diseases, viral diseases, cancer, and amyloid disorders. Thus, a capsule contained a thieno[2,3-c]pyridine 40.0, starch 109.0, and Mg stearate 1.0 mg.
IT 533904-03-9P 738620-45-6P
RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(pharmaceutical compns. comprising thieno[2,3-c]pyridines)
RN 533904-03-9 CAPLUS
CN Thieno[2,3-c]pyridine-3-carboxamide, 6-ethyl-4,5,6,7-tetrahydro-N-methyl-2-[[4-([methylphenylamino)sulfonyl]benzoyl]amino]- (CA INDEX NAME)

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 738620-45-6 CAPLUS
CN Thieno[2,3-c]pyridine-3-carboxamide, 6-ethyl-4,5,6,7-tetrahydro-2-[[4-([methyl-1-piperazinyl)sulfonyl]benzoyl]amino]- (CA INDEX NAME)




IT 440334-81-6 449767-27-5 449767-88-8
449767-89-9 449768-16-5 449768-37-0
449768-51-8 449768-53-0 449768-67-6
449768-77-8 449768-83-6 449768-27-1
486453-13-8 486453-14-9 486453-16-1
486453-17-2 486453-18-3 486453-20-7
486453-21-8 486453-22-9 486453-24-1
486453-25-2 486453-26-3 486453-27-4
486453-29-6 489470-30-6 489470-38-4
489470-54-4 489470-89-5 489470-97-5
489470-98-6 489471-00-3 489471-01-4
489471-04-7 489471-11-6 489471-16-1
489471-25-2 489471-29-6 489471-31-0
489471-38-7 489471-39-8 524694-99-3
524695-12-3 524706-73-8 533995-61-3
533904-54-0 681264-20-0 681439-14-5
681439-15-6 738620-43-4 738620-44-5
738620-48-9 738620-49-0 738620-50-3
RI: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. comprising thieno[2,3-c]pyridines)
RN 440334-81-6 CAPLUS
CN Thieno[2,3-c]pyridine-3-carboxylic acid, 2-[[4-([diethylamino)sulfonyl]benzoyl]amino]-4,5,6,7-tetrahydro-5,5,7,7-tetramethyl-, ethyl ester (CA INDEX NAME)




RN 449767-27-5 CAPLUS
CN Thieno[2,3-c]pyridine-3-carboxamide, 4,5,6,7-tetrahydro-6-methyl-2-[[4-((1,3,3-trimethyl-6-azabicyclo[3.2.1]oct-6-yl)sulfonyl)benzoyl]amino]- (CA INDEX NAME)




RN 449767-88-8 CAPLUS
CN Benzamide, N-[3-(2-benzothiazolyl)-6-ethyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-2-yl]-4-[(diethylamino)sulfonyl]- (CA INDEX NAME)




RN 449767-89-9 CAPLUS
CN Benzamide, N-[3-(2-benzothiazolyl)-6-ethyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-2-yl]-4-[(butylethylamino)sulfonyl]- (CA INDEX NAME)




RN 449768-53-0 CAPLUS
CN Thieno[2,3-c]pyridine-3-carboxamide, 4,5,6,7-tetrahydro-6-(1-methylethyl)-2-[[4-[(methylphenylamino)sulfonyl]benzoyl]amino]- (CA INDEX NAME)




RN 449768-67-6 CAPLUS
CN Thieno[2,3-c]pyridine-3-carboxamide, 2-[[4-[(3,5-dimethyl-1-piperidinyl)sulfonyl]benzoyl]amino]-4,5,6,7-tetrahydro-6-(1-methylethyl)- (CA INDEX NAME)




RN 449768-77-8 CAPLUS
CN Thieno[2,3-c]pyridine-3-carboxamide, 2-[[4-[(3,4-dihydro-2(1H)-isoquinolinyl)sulfonyl]benzoyl]amino]-4,5,6,7-tetrahydro-6-(1-methylethyl)- (CA INDEX NAME)




RN 449768-16-5 CAPLUS
CN Thieno[2,3-c]pyridine-3-carboxylic acid, 2-[[4-[(butylmethylamino)sulfonyl]benzoyl]amino]-4,5,6,7-tetrahydro-6-(1-methylethyl)-, ethyl ester (CA INDEX NAME)




RN 449768-37-0 CAPLUS
CN Thieno[2,3-c]pyridine-3-carboxylic acid, 2-[[4-[(3,4-dihydro-1(2H)-quinolinyl)sulfonyl]benzoyl]amino]-4,5,6,7-tetrahydro-6-(1-methylethyl)-, ethyl ester (CA INDEX NAME)




RN 449768-51-8 CAPLUS
CN Thieno[2,3-c]pyridine-3-carboxamide, 2-[[4-[(butylethylamino)sulfonyl]benzoyl]amino]-4,5,6,7-tetrahydro-6-(1-methylethyl)- (CA INDEX NAME)




RN 449768-83-6 CAPLUS
CN Benzamide, N-[3-(2-benzothiazolyl)-4,5,6,7-tetrahydro-6-(1-methylethyl)thieno[2,3-c]pyridin-2-yl]-4-[(diethylamino)sulfonyl]- (CA INDEX NAME)




RN 449783-27-1 CAPLUS
CN Thieno[2,3-c]pyridine-3-carboxylic acid, 2-[[4-[(hexahydro-1H-azepin-1-yl)sulfonyl]benzoyl]amino]-4,5,6,7-tetrahydro-5,5,7,7-tetramethyl-, ethyl ester (CA INDEX NAME)




RN 486453-13-8 CAPLUS
CN Benzamide, N-[3-(2-benzothiazolyl)-4,5,6,7-tetrahydro-6-methylthieno[2,3-c]pyridin-2-yl]-4-[(diethylamino)sulfonyl]- (CA INDEX NAME)




RN 486453-14-9 CAPLUS
CN Benzamide, N-[3-(2-benzothiazolyl)-4,5,6,7-tetrahydro-6-methylthieno[2,3-c]pyridin-2-yl]-4-[(dipropylamino)sulfonyl]- (CA INDEX NAME)




RN 486453-16-1 CAPLUS
CN Benzamide, N-[3-(2-benzothiazolyl)-4,5,6,7-tetrahydro-6-methylthieno[2,3-c]pyridin-2-yl]-4-[(di-tert-butylamino)sulfonyl]- (CA INDEX NAME)




RN 486453-17-2 CAPLUS
CN Benzamide, N-[3-(2-benzothiazolyl)-4,5,6,7-tetrahydro-6-methylthieno[2,3-c]pyridin-2-yl]-4-[(di-tert-butylamino)sulfonyl]- (CA INDEX NAME)




RN 486453-22-9 CAPLUS
CN Benzamide, N-[3-(2-benzothiazolyl)-4,5,6,7-tetrahydro-6-methylthieno[2,3-c]pyridin-2-yl]-4-(1-piperidinylsulfonyl)- (CA INDEX NAME)




RN 486453-24-1 CAPLUS
CN Benzamide, N-[3-(2-benzothiazolyl)-4,5,6,7-tetrahydro-6-methylthieno[2,3-c]pyridin-2-yl]-4-[(3-methyl-1-piperidinyl)sulfonyl]- (CA INDEX NAME)




RN 486453-25-2 CAPLUS
CN Benzamide, N-[3-(2-benzothiazolyl)-4,5,6,7-tetrahydro-6-methylthieno[2,3-c]pyridin-2-yl]-4-[(4-methyl-1-piperidinyl)sulfonyl]- (CA INDEX NAME)




RN 486453-18-3 CAPLUS
CN Benzamide, N-[3-(2-benzothiazolyl)-4,5,6,7-tetrahydro-6-methylthieno[2,3-c]pyridin-2-yl]-4-[(butylethylamino)sulfonyl]- (CA INDEX NAME)




RN 486453-20-7 CAPLUS
CN Benzamide, N-[3-(2-benzothiazolyl)-4,5,6,7-tetrahydro-6-methylthieno[2,3-c]pyridin-2-yl]-4-[(di-2-propenylamino)sulfonyl]- (9CI) (CA INDEX NAME)




RN 486453-21-8 CAPLUS
CN Benzamide, N-[3-(2-benzothiazolyl)-4,5,6,7-tetrahydro-6-methylthieno[2,3-c]pyridin-2-yl]-4-(1-pyrrolidinylsulfonyl)- (CA INDEX NAME)




RN 486453-26-3 CAPLUS
CN Benzamide, N-[3-(2-benzothiazolyl)-4,5,6,7-tetrahydro-6-methylthieno[2,3-c]pyridin-2-yl]-4-[(3,5-dimethyl-1-piperidinyl)sulfonyl]- (CA INDEX NAME)




RN 486453-27-4 CAPLUS
CN Benzamide, N-[3-(2-benzothiazolyl)-4,5,6,7-tetrahydro-6-methylthieno[2,3-c]pyridin-2-yl]-4-(4-morpholinylsulfonyl)- (CA INDEX NAME)




RN 486453-29-6 CAPLUS
CN Benzamide, N-[3-(2-benzothiazolyl)-4,5,6,7-tetrahydro-6-methylthieno[2,3-c]pyridin-2-yl]-4-[(bis(2-methoxyethyl)amino)sulfonyl]- (CA INDEX NAME)




RN 489470-30-6 CAPLUS
CN Benzamide, N-[3-(2-benzothiazolyl)-6-ethyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-2-yl]-4-[(dipropylamino)sulfonyl]- (CA INDEX NAME)




RN 489470-38-4 CAPLUS
CN Benzamide, N-[3-(2-benzothiazolyl)-6-ethyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-2-yl]-4-[(di-2-propenylamino)sulfonyl]- (9CI) (CA INDEX NAME)




RN 489470-54-4 CAPLUS
CN Benzamide, N-[3-(2-benzothiazolyl)-6-ethyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-2-yl]-4-[(hexahydro-1H-azepin-1-yl)sulfonyl]- (CA INDEX NAME)




RN 489471-00-3 CAPLUS
CN Benzamide, N-[3-(2-benzothiazolyl)-4,5,6,7-tetrahydro-6-(1-methylethyl)thieno[2,3-c]pyridin-2-yl]-4-(1-piperidinylsulfonyl)- (CA INDEX NAME)




RN 489471-01-4 CAPLUS
CN Benzamide, N-[3-(2-benzothiazolyl)-4,5,6,7-tetrahydro-6-(1-methylethyl)thieno[2,3-c]pyridin-2-yl]-4-[(2-methyl-1-piperidinyl)sulfonyl]- (CA INDEX NAME)




RN 489471-04-7 CAPLUS
CN Benzamide, N-[3-(2-benzothiazolyl)-4,5,6,7-tetrahydro-6-(1-




RN 489470-89-5 CAPLUS
CN Thieno[2,3-c]pyridine-3-carboxylic acid, 2-[[4-[(ethoxycarbonyl)-1-piperazinylsulfonyl]benzoyl]amino]-4,5,6,7-tetrahydro-6-(1-methylethyl)-, ethyl ester (CA INDEX NAME)




RN 489470-97-5 CAPLUS
CN Benzamide, N-[3-(2-benzothiazolyl)-4,5,6,7-tetrahydro-6-(1-methylethyl)thieno[2,3-c]pyridin-2-yl]-4-[(butylethylamino)sulfonyl]- (CA INDEX NAME)




RN 489470-98-6 CAPLUS
CN Benzamide, N-[3-(2-benzothiazolyl)-4,5,6,7-tetrahydro-6-(1-methylethyl)thieno[2,3-c]pyridin-2-yl]-4-[(di-2-propenylamino)sulfonyl]- (9CI) (CA INDEX NAME)




RN 489471-11-6 CAPLUS
CN Thieno[2,3-c]pyridine-6(5H)-carboxylic acid, 3-(2-benzothiazolyl)-2-[[4-[(diethylamino)sulfonyl]benzoyl]amino]-4,7-dihydro-, ethyl ester (CA INDEX NAME)




RN 489471-16-1 CAPLUS
CN Thieno[2,3-c]pyridine-3-carboxylic acid, 2-[[4-[(di-2-propenylamino)sulfonyl]benzoyl]amino]-4,5,6,7-tetrahydro-5,5,7,7-tetramethyl-, methyl ester (9CI) (CA INDEX NAME)




RN 489471-25-2 CAPLUS
CN Thieno[2,3-c]pyridine-3-carboxamide, 2-[[4-[(diethylamino)sulfonyl]benzoyl]amino]-4,5,6,7-tetrahydro-5,5,7,7-tetramethyl- (CA INDEX NAME)




RN 489471-29-6 CAPLUS
CN Thieno[2,3-c]pyridine-3-carboxamide, 2-[[4-[(butylmethylamino)sulfonyl]benzoyl]amino]-4,5,6,7-tetrahydro-5,5,7,7-tetramethyl- (CA INDEX NAME)




RN 489471-31-0 CAPLUS
CN Thieno[2,3-c]pyridine-3-carboxamide, 2-[[4-[(cyclohexylmethylamino)sulfonyl]benzoyl]amino]-4,5,6,7-tetrahydro-5,5,7,7-tetramethyl- (CA INDEX NAME)




RN 489471-38-7 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[4-[[[3-(aminocarbonyl)-4,5,6,7-tetrahydro-5,5,7,7-tetramethylthieno[2,3-c]pyridin-2-yl]amino]carbonyl]phenyl]sulfonyl]-, ethyl ester (CA INDEX NAME)




RN 524706-73-8 CAPLUS
CN Benzamide, N-[3-(2-benzothiazolyl)-4,5,6,7-tetrahydro-6-methylthieno[2,3-c]pyridin-2-yl]-4-[(1,3,3-trimethyl-6-azabicyclo[3.2.1]oct-6-yl)sulfonyl]- (CA INDEX NAME)




RN 533895-61-3 CAPLUS
CN Thieno[2,3-c]pyridine-3-carboxamide, 2-[[4-[(3,4-dihydro-1(2H)-isoquinolinyl)sulfonyl]benzoyl]amino]-4,5,6,7-tetrahydro-5,5,7,7-tetramethyl- (CA INDEX NAME)




RN 533904-54-0 CAPLUS
CN Thieno[2,3-c]pyridine-3-carboxamide, 2-[[4-[(diethylamino)sulfonyl]benzoyl]amino]-4,5,6,7-tetrahydro-5,5,7,7-tetramethyl- (CA INDEX NAME)




RN 489471-39-8 CAPLUS
CN Thieno[2,3-c]pyridine-3-carboxamide, 2-[[4-[(3,4-dihydro-1(2H)-isoquinolinyl)sulfonyl]benzoyl]amino]-4,5,6,7-tetrahydro-5,5,7,7-tetramethyl- (CA INDEX NAME)




RN 524694-99-3 CAPLUS
CN Benzamide, N-[3-(2-benzothiazolyl)-4,5,6,7-tetrahydro-6-methylthieno[2,3-c]pyridin-2-yl]-4-[(diethylamino)sulfonyl]- (CA INDEX NAME)




RN 524695-12-3 CAPLUS
CN Benzamide, N-[3-(2-benzothiazolyl)-4,5,6,7-tetrahydro-6-methylthieno[2,3-c]pyridin-2-yl]-4-[(methylphenylamino)sulfonyl]- (CA INDEX NAME)



RN 681264-20-0 CAPLUS
CN Benzamide, N-[3-(2-benzothiazolyl)-4,5,6,7-tetrahydro-6-methylthieno[2,3-c]pyridin-2-yl]-4-[(3,4-dihydro-1(2H)-isoquinolinyl)sulfonyl]- (CA INDEX NAME)




RN 681439-14-5 CAPLUS
CN Thieno[2,3-c]pyridine-3-carboxamide, 2-[[4-[(3,4-dihydro-2(1H)-isoquinolinyl)sulfonyl]benzoyl]amino]-4,5,6,7-tetrahydro-5,5,7,7-tetramethyl- (CA INDEX NAME)




RN 681439-15-6 CAPLUS
CN Thieno[2,3-c]pyridine-3-carboxamide, 2-[[4-[(bis(2-ethylamino)ethyl)sulfonyl]benzoyl]amino]-4,5,6,7-tetrahydro-5,5,7,7-tetramethyl- (CA INDEX NAME)

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 methoxyethylamino)sulfonylbenzoyl amino]-4,5,6,7-tetrahydro-5,5,7,7-tetramethyl- (CA INDEX NAME)




RN 738620-43-4 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[[[4-[[[3-(2-benzothiazolyl)-4,5,6,7-tetrahydro-6-methylthieno[2,3-c]pyridin-2-yl]amino]carbonyl]phenyl]sulfonyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)





● HCl

RN 738620-44-5 CAPLUS
 CN Thieno[2,3-c]pyridine-3-carboxamide, 6-ethyl-2-[[[4-[[[ethyl(phenylmethyl)amino]sulfonyl]benzoyl]amino]-4,5,6,7-tetrahydro- (CA INDEX NAME)




L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 738620-48-9 CAPLUS
 CN Thieno[2,3-c]pyridine-3-carboxamide, 6-ethyl-4,5,6,7-tetrahydro-N-methyl-2-[[[4-[[[4-methyl-1-piperazinyl]sulfonyl]benzoyl]amino]- (CA INDEX NAME)




RN 738620-49-0 CAPLUS
 CN Benzamide, N-[3-(2-benzothiazolyl)-6-ethyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-2-yl]-4-[[[4-methyl-1-piperazinyl]sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 738620-50-3 CAPLUS
 CN Thieno[2,3-c]pyridine-3-carboxamide, 2-[[[4-[[[diethylamino]sulfonyl]benzoyl]amino]-6-ethyl-4,5,6,7-tetrahydro-N-4-morpholinyl]- (CA INDEX NAME)

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2002:826913 CAPLUS
 DOCUMENT NUMBER: 138:49321
 TITLE: Property-based design of GPCR-targeted library
 AUTHOR(S): Balakin, Konstantin V.; Tkachenko, Sergey E.; Lang, Stanley A.; Okun, Ilya; Ivashchenko, Andrey A.; Savchuk, Nikolay P.
 CORPORATE SOURCE: Chemical Diversity Labs Inc., San Diego, CA, 92121, USA
 SOURCE: Journal of Chemical Information and Computer Sciences (2002), 42(6), 1332-1342
 CODEN: JCISDH; ISSN: 0095-2338
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The design of a GPCR-targeted library, based on a scoring scheme for the classification of mols. into "GPCR-ligand-like" and "non-GPCR-ligand-like", is outlined. The methodol. is a valuable tool that can aid in the selection and prioritization of potential GPCR ligands for bioscreening from large collections of compds. It is based on the distillation of knowledge from large databases of GPCR and non-GPCR active agents. The method employed a set of descriptors for encoding the mol. structures and by training of a neural network for classifying the mols. The mol. requirements were profiled and validated by using available databases of GPCR- and non-GPCR-active agents. The method enables efficient qualification or disqualification of a mol. as a potential GPCR ligand and represents a useful tool for constraining the size of GPCR-targeted libraries that will help speed up the development of new GPCR-active drugs.
 IT 478932-86-4
 RL: PAC (Pharmacological activity); THRU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (property-based design of GPCR-targeted library)
 RN 478932-86-4 CAPLUS
 CN Thieno[2,3-c]pyridine-3-carboxylic acid, 6-ethyl-4,5,6,7-tetrahydro-2-[[[4-[[[4,6,6-trimethyl-2-azabicyclo[2.2.1]hept-2-yl]sulfonyl]benzoyl]amino]-, ethyl ester (CA INDEX NAME)



REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 11:14:33 ON 12 DEC 2007)

FILE 'REGISTRY' ENTERED AT 11:14:43 ON 12 DEC 2007

L1 STRUCTURE UPLOADED
L2 50 S L1
L3 3524 S L1 FULL

FILE 'CAPLUS' ENTERED AT 11:15:11 ON 12 DEC 2007

L4 3 S L3 FULL

=> log y

COST IN U.S. DOLLARS

SINCE FILE
ENTRY

TOTAL
SESSION

FULL ESTIMATED COST

16.28

188.59

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE
ENTRY

TOTAL
SESSION

CA SUBSCRIBER PRICE

-2.34

-2.34

STN INTERNATIONAL LOGOFF AT 11:15:51 ON 12 DEC 2007